In this episode of Drug Diaries, Geert Kersten, CEO of Cel-Sci, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer treatment. He emphasizes the importance of the immune system in fighting cancer and the need for a paradigm shift in how cancer therapies are developed and administered. The conversation covers the challenges faced in drug development, regulatory hurdles, and the potential impact of Multikine on head and neck cancer treatment. Geert also shares insights on the evolving healthcare landscape in Saudi Arabia and the future aspirations for Multikine and Cel-Sci. Chapters 00:00 The Journey of Immunotherapy in Cancer Treatment 09:24 Understanding Multikine and Its Impact on Head and Neck Cancer 18:56 The Science Behind Multikine: Mechanism and Administration 23:27 Navigating Challenges: Regulatory Hurdles and Market Dynamics 26:21 FDA Feedback and Study Design 29:21 Commercial Aspirations and Future Vision 31:36 Saudi Arabia's Healthcare Vision 2030 35:04 Breakthrough Designation Explained 37:40 Multikine's Role in Cancer Treatment 41:03 Dealing with Doubt and Investor Skepticism 44:53 The Future of Leap Platforms 46:48 Long-term Impact of Multikine